Original language | English |
---|---|
Pages (from-to) | E146-E149 |
Journal | American Journal of Hematology |
Volume | 94 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Journal of Hematology, Vol. 94, No. 5, 05.2019, p. E146-E149.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group
AU - Bustoros, Mark
AU - Kastritis, Efstathios
AU - Sklavenitis-Pistofidis, Romanos
AU - Liu, Chia Jen
AU - Hornburg, Kalvis
AU - Kanellias, Nikolaos
AU - Kim, Geon
AU - Liu, David
AU - Gavriatopoulou, Maria
AU - Marinac, Catherine R.
AU - Roussou, Maria
AU - Migkou, Magdalini
AU - Noonan, Kimberly
AU - Reyes, Kaitlen
AU - Rivotto, Bradley
AU - Neuse, Carl Jannes
AU - Ziogas, Dimitrios C.
AU - Laubach, Jacob
AU - Terpos, Evangelos
AU - Anderson, Kenneth C.
AU - Richardson, Paul G.
AU - Ghobrial, Irene M.
AU - Dimopoulos, Meletios A.
N1 - Funding Information: This study was supported in part by National Institutes of Health grant (NIH R01 CA 205954 and F32 CA220859) and Multiple Myeloma Research Foundation (MMRF)—Perelman Family Foundation grant for early detection and prevention of Multiple Myeloma. Funding Information: M.B. has advisory role and received honoraria from Takeda. E.K. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda, Prothena, M.A.D. has received honoraria from Amgen, Celgene, Janssen, Takeda. E.T. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda. K.C.A. has advisory role in Celgene, Takeda, Bristol-Myers Squibb (BMS), Janssen, Sanofi, and Gilead. K.C.A. is a scientific founder of OncoPep and C4 therapeutics. P.G.R. has a consulting role and has received research funding from Karyopharm, Oncopeptides, Celgene, Takeda, Amgen, and Janssen. I.M.G. has a consulting/advisory role and has received research funding from Celgene, Takeda, BMS, Janssen Pharmaceuticals, and Amgen.
PY - 2019/5
Y1 - 2019/5
UR - http://www.scopus.com/inward/record.url?scp=85062684005&partnerID=8YFLogxK
U2 - 10.1002/ajh.25441
DO - 10.1002/ajh.25441
M3 - Letter
C2 - 30773670
AN - SCOPUS:85062684005
SN - 0361-8609
VL - 94
SP - E146-E149
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 5
ER -